The Effect of Azithromycin on Relapse in Patients with Moderate-Severe Chronic Graft Versus Host Disease (CGVHD)
Mark Shamoun, Gregory A. Yanik(University of Michigan), Attaphol Pawarode(University of Michigan), Ghada Abusin, Thomas Braun(Justus-Liebig-Universität Gießen), Mary Riwes(University of Michigan), Monalisa Ghosh(Michigan Medicine), Challice L. Bonifant(Johns Hopkins University), Sung Won Choi(University of Michigan), Mark Vander Lugt(Pediatrics and Genetics), Sarah Anand(University of Michigan), Carrie L. Kitko(Vanderbilt University Medical Center), Pavan Reddy(Wichita State University), Dan Peltier(University of Michigan), Brian Parkin(AdventHealth Orlando), John Magenau(University of Michigan)
Cited by 6
Related Papers
Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia
|New England Journal of Medicine|2018|5.7k
National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group Report
|Biology of Blood and Marrow Transplantation|2014|5.4k
Gut microbiome–derived metabolites modulate intestinal epithelial cell damage and mitigate graft-versus-host disease
|Nature Immunology|2016|727
Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial
|Nature Medicine|2021|523
Pax7 directs postnatal renewal and propagation of myogenic satellite cells but not their specification
|The EMBO Journal|2004|511